The ISPOR 23rd Annual International Meeting in Baltimore, Maryland, on May 19-23 is almost here, and Precision Health Economics (PHE) and Precision Xtract will be there ready to meet with you and share our expertise. With over 25 of our top experts in attendance, Precision thought leaders will be participating in a number of scientific presentations, including an issue panel, a podium presentation, and presenting 10 posters.
In addition, we’ll be on the convention floor at Booth #701 and look forward to meeting colleagues there, too.
To meet with a Precision expert at ISPOR, please email us at info@precisionhealtheconomics.com.
For a complete list of our scientific participation, including schedule and details, please see below:
ISSUE PANEL:
Monday, May 21, 5:00 PM – 6:00 PM
IP5: “Should We Move Beyond Conventional Cost-Effectiveness Analysis? If So, How?”
Moderator:
Darius N. Lakdawalla, PhD (PHE Chief Scientific Officer)
Panelists:
Peter J. Neumann, ScD; Charles E. Phelps, PhD, MBA; Jeroen Jansen, PhD
Overview:
As health care systems increasingly move toward value-oriented decision-making, decision-analytic approaches must provide more flexibility than they have previously. Calls for inclusion of broader components of value – such as health equity, for example – challenge researchers to think beyond the traditional structure of CEA, which compares health interventions in terms of incremental costs relative to incremental gains (or losses) in quality-adjusted life years (QALYs). Meanwhile, some observers argue that the QALY does not adequately capture treatment attributes important to decision-makers, especially patients. Expansions of CEA and alternative approaches, such as multi-criteria decision analysis, have been proposed, but application of these approaches to real-world value comparisons – where diverse stakeholder perspectives may call for multiple approaches – presents considerable challenges. The panel will discuss alternative approaches to improving the flexibility and responsiveness of healthcare technology assessment, with particular focus on the role of MCDA and of flexible, open-source decision models.
PODIUM PRESENTATION:
Monday, May 21, 5:00 PM – 5:15 PM
CS1: “A Budget Impact Model of Axicabtagene Ciloleucel (AXI-CEL) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (RR-LBCL)”
Authors: Hathway J, Purdum AG, Lin VW, Cyr PL, Westin JR, Jansen IS
POSTERS:
Poster Presentation Session I
Monday, May 21
Poster display: 8:30 AM – 2:00 PM
Author discussion: 1:00 PM – 2:00 PM
PMS28: “The Effect of Medication Choice After Tumor Necrosis Factor Inhibitor (TNFI) Use on the Healthcare Costs for Patients With Rheumatoid Arthritis: An Instrumental Variables Approach”
Authors: Shahabi A, Shafrin J, Zhao L, Green S, Marshall A, Curtice T, D Paul
PRM77: “An Open-Source Toolkit for Developing Flexible Evidence-Based Decision and Simulation Models for Value Assessment in Oncology with R”
Authors: Incerti D, Jansen JP
PRM79: “Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios”
Authors: Wu E, Keeping S, Chan K, Mojebi A, Balakumaran A
PMS31: “Quantifying the Importance of Model Parameters and Structural Assumptions on the Value of Treatments for Rheumatoid Arthritis Using Metamodeling”
Authors: Incerti D, Jansen JP
Poster Presentation Session II
Monday, May 21
Poster display: 3:30 PM – 7:30 PM
Author discussion: 6:30 PM – 7:30 PM
PDB32: “Comparison of Healthcare Resource Utilization and Clinical Status Among Type 2 Diabetes Patients Using Multiple-Daily Injection (MDI) Insulin Therapy Versus Non-MDI Therapy”
Authors: Ludden T, Ermakova A, Xiong Y, Sieradzan R, Sacks N, Cyr P, Phillips S, Taylor S
Poster Presentation Session III
Tuesday, May 22
Poster display: 8:30 AM – 2:00 PM
Author discussion: 1:00 PM – 2:00 PM
PHP216: “The Impact of Lifting Government Price Controls on Global Pharmaceutical Innovation and Population Health”
Authors: Schwartz TT, Ward AS, Sullivan J
PMH49: “Outcomes Among Patients Prescribed Atypical Long-Acting Injectables Vs Oral Antipsychotic Therapy Following an Acute Event for Schizophrenia”
Authors: Shrestha A, Shah A, Everson K, Huber C, Seabury S, O’Sullivan AK, Weiden PJ
Poster Presentation Session IV
Tuesday, May 22
Poster display: 3:30 PM – 7:30 PM
Author discussion: 6:30 PM – 7:30 PM
PCN16: “Approaches for Estimating the Comparative Efficacy of Treatments for Patients with Recurrent Small Cell Lung Cancer (SCLC) Within Connected and Disconnected Networks of Evidence”
Authors: Cope S, Keeping ST, Barazandegan M, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez Garcia A, Yuan Y
PCN196: “The Long-Term Social Value of Better Targeting G-SCF Therapy to Cancer Patients at Risk of Febrile Neutropenia”
Authors: Ward AS, Kabiri M, Yucel A, Silverstein AR, van Eijndhoven E, Bowers C, Bensink M, Goldman DP
PGI33: “Impact of Medicaid Treatment Access Policies on the Hepatitis C Epidemic”
Authors: Chou JW, Silverstein AR, Goldman DP
